Last update 01 Nov 2024

Glycopyrronium Bromide/Rivastigmine

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Glycopyrrolate/rivastigmine
Target
AChE x mAChRs
Mechanism
AChE inhibitors(Acetylcholinesterase inhibitors), mAChRs antagonists(Muscarinic acetylcholine receptor antagonists)
Therapeutic Areas
Nervous System DiseasesEndocrinology and Metabolic Disease
Active Indication-
Inactive Indication
Alzheimer DiseaseLewy Body Disease
Originator Organization
Axovant Holdings Ltd.
Active Organization-
Inactive Organization
Axovant Holdings Ltd.Qaam Pharmaceuticals LLCAxovant Sciences, Inc.
Drug Highest PhaseDiscontinuedPhase 1
First Approval Date-
Regulation-
Login to view timeline

Structure

Molecular FormulaC19H28BrNO3
InChIKeyVPNYRYCIDCJBOM-HPUDQCTASA-M
CAS Registry51186-83-5
View All Structures (3)

Related

2
Clinical Trials associated with Glycopyrronium Bromide/Rivastigmine
NCT05985343 / RecruitingPhase 4IIT
The Impact of Sugammadex on Ileus After Abdominal Wall Reconstruction
EUCTR2015-005565-23-LV / Not yet recruitingPhase 2
A multicenter, randomized, double-blind, placebo-controlled 3-period complete cross-over study to assess the bronchodilator effects and safety of glycopyrronium bromide (NVA237) (25 µg and 50 µg o.d.) in asthma patients
100 Clinical Results associated with Glycopyrronium Bromide/Rivastigmine
Login to view more data
100 Translational Medicine associated with Glycopyrronium Bromide/Rivastigmine
Login to view more data
100 Patents (Medical) associated with Glycopyrronium Bromide/Rivastigmine
Login to view more data
100 Deals associated with Glycopyrronium Bromide/Rivastigmine
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Alzheimer DiseasePhase 1-
Qaam Pharmaceuticals LLC
-
Alzheimer DiseasePhase 1
US
Axovant Sciences, Inc.
-
Alzheimer DiseasePhase 1-
Axovant Holdings Ltd.
-
Lewy Body DiseasePhase 1-
Qaam Pharmaceuticals LLC
-
Lewy Body DiseasePhase 1
US
Axovant Sciences, Inc.
-
Lewy Body DiseasePhase 1-
Axovant Holdings Ltd.
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
AAIC2013
Not Applicable
-
-
hjyicsbwsz(fkawqdwptu) = olrathwrqv vruwbhioqu (jzcoquqaqn )
-
01 Jul 2013
hjyicsbwsz(fkawqdwptu) = asdzyyhave vruwbhioqu (jzcoquqaqn )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free